Tumor-Specific Immuno-Gene Therapy (T-SIGn®) is a clinically validated, systemically-dosed, viral vector platform that enables tumor-localized production of immunotherapeutics that, in effect, turn cancer cells into “drug factories” that drive sustained reprogramming of the tumor microenvironment in both primary and metastatic tumor sites.
The exquisitely engineered T-SIGn® viral vectors deliver combinations of transgenes encoding protein therapeutics and synthetic payloads in a single product to target multiple mechanistic barriers within solid tumors.
The platform uses enadenotucirev, a blood-stable chimeric group B adenovirus, as a viral vector system for the delivery of therapeutic transgenes to cancer cells, taking advantage of the clinically demonstrated tumor selectivity and intravenous delivery properties of this virus. The platform is highly leverageable to many different therapies, targeting relevant mechanistic barriers to treatment.
T-SIGn® viral vectors can be specifically designed to act as a monotherapy or to work in synergy with other agents, such as cellular therapies, which are otherwise poorly effective in a solid tumor setting.
Transgene Armed Vector Genome
Chemokines Synthetic Payloads
PROPRIETARY VECTOR SYSTEM
Allows up to five transgenes providing tumor-specific expression of novel payload combinations in one treatment modality
Standard of care or other
(e.g. CAR T-cell therapy)
Targets primary and metastatic tumors
as a monotherapy or in combination
(e.g with CAR T-cell therapy)
and Payload Production
Harness endogenous immunity
Express T cell chemo-attractants
Express cytokines, antibodies or other immunomodulators
Cell surface or spray-painted antigens
Activate and direct exogenous therapies
The possibilities are endless.
Marrying our mastery of vector design with our deep expertise in immunology and biology of the tumor microenvironment opens a multitude of potential opportunities for innovative combination therapeutic approaches for treating cancer.
In addition to conventional biologic molecules, such as antibodies, antibody fragments, bi-specifics, cytokines, chemokines and other immunomodulators, we are also exploring novel synthetic payload designs as we build an exciting and powerful pipeline of new T-SIGn® candidates, both independently and through partnership.
The clinically demonstrated capability of our vectors to selectively produce their transgene payloads in tumor cells following intravenous infusion has enabled us to break free from the constraints hampering traditional oncolytic viruses, potentially enabling the treatment of patients with both primary and metastatic disease.
We are experts at designing vector constructs, and the payload opportunities are endless. Our T-SIGn® tumor re-programming technology extends beyond traditional oncolytic viruses and we are continuing to explore other novel synthetic payloads and ways of combining more agents to develop a powerful pipeline of new T-SIGn® opportunities. These can include antibody fragments, bispecifics, engagers, and other immune-modulators, rationally designed to target specific tumor indications.